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Background: A significant minority of patients do not receive all the evidence-based care recommended for their
conditions. Health care quality may be improved by reducing this observed variation. Composite measures offer a
different patient-centred perspective on quality and are utilized in acute hospitals via the ‘care bundle’ concept as
indicators of the reliability of specific (evidence-based) care delivery tasks and improved outcomes. A care bundle
consists of a number of time-specific interventions that should be delivered to every patient every time. We aimed
to apply the care bundle concept to selected QOF data to measure the quality of evidence-based care provision.
Methods: Care bundles and components were selected from QOF indicators according to defined criteria. Five
clinical conditions were suitable for care bundles: Secondary Prevention of Coronary Heart Disease (CHD), Stroke &
Transient Ischaemic Attack (TIA), Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD) and
Diabetes Mellitus (DM). Each bundle has 3-8 components. A retrospective audit was undertaken in a convenience
sample of nine general medical practices in the West of Scotland. Collected data included delivery (or not) of
individual bundle components to all patients included on specific disease registers. Practice level and overall
compliance with bundles and components were calculated in SPSS and expressed as a percentage.
Results: Nine practices (64.3%) with a combined patient population of 56,948 were able to provide data in the
format requested. Overall compliance with developed QOF-based care bundles (composite measures) was as
follows: CHD 64.0%, range 35.0-71.9%; Stroke/TIA 74.1%, range 51.6-82.8%; CKD 69.0%, range 64.0-81.4%; and COPD
82.0%, range 47.9-95.8%; and DM 58.4%, range 50.3-65.2%.
Conclusions: In this small study compliance with individual QOF-based care bundle components was high, but
overall (‘all or nothing’) compliance was substantially lower. Care bundles may provide a more informed measure of
care quality than existing methods. However, the acceptability, feasibility and potential impact on clinical outcomes
are unknown.Background
Wide variation in the provision of evidence-based care is
recognized as a fundamental issue in all health care sys-
tems worldwide. The consequences of such variation
often impact negatively on patients in terms of health
care quality, safety, experiences and increased financial
costs (including additional treatments and litigation)
associated with sub-optimal clinical practices [1,2].* Correspondence: paul.bowie@nes.scot.nhs.uk
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reproduction in any medium, provided the orIt is widely accepted that there is a need to minimize
unnecessary variation to improve the reliability of best
practice care provision and the associated financial costs
[2-4]. Practicing evidence-based medicine and imple-
menting clinical care guidelines are promoted to assist
clinical decision making and optimal management of
patients, but does not necessarily ensure that patients
who should receive all appropriate care actually do so
[5-8].
Around 50% of hospital patients may receive the full
recommended care and treatments which their clinical
condition merits. The difference between the highest
and lowest performing health care systems suggests thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mended) care provision [1,9]. In primary care settings,
evidence of wide variation has also been found between
individual health care providers [10]. For example, in
general medical practice in the United Kingdom (UK)
substantial variation in patient care has been described
in anxiolytic, hypnotic, antidepressant and antibiotic pre-
scribing [11-13].
The Quality & Outcomes Framework (QOF) is a pay-
for-performance (P4P) scheme that was introduced to UK
general practice in April 2004 to help address longstand-
ing variation in the quality of primary care provision [14].
Clinical conditions are suitable for QOF inclusion and
therefore financial incentivisation if they are common,
associated with significant morbidity (and to a lesser ex-
tent mortality), and are diagnostically unambiguous. Indi-
cators should be evidence based, achievable by every
primary care team, clearly defined and consistently ex-
tractable from different computerized information systems
[14].
Since 2009, QOF indicators have been developed
through a rigorous National Institute for Clinical Excel-
lence (NICE) led process which includes input from an
expert panel and extensive piloting [14]. The Framework
consists of a number of incentivized ‘point-in-time’ indi-
cators arranged into four main groups: additional ser-
vices, patient experience, organizational and clinical
sections [15]. Practices ‘earn’ points according to their
level of achievement for each indicator, with payment
currently starting at a minimum threshold (usually 40%)
rising to a maximum (usually 90%).
The average achievement of available QOF points for
the period April 2009 to March 2010 was 93.7% in gen-
eral practices in England and 97.2% in Scotland [16,17].
The implication is that the quality of care delivered by
practices to patients with incentivized disease conditions
is very high. However, there is some concern that max-
imum payment thresholds for QOF indicators are actu-
ally too low and that the high performances achieved by
most practices may give the inaccurate impression that
care quality does not necessarily need to be improved
further [18,19].
There is growing interest in the use of composite – as
well as individual - measures of care delivery as an alter-
native method of describing the quality of clinical care
processes and outcomes [10]. The main benefit of the
composite (‘all or nothing’) approach is that it may high-
light opportunities for further improvement in care
provision even when individual measures already indi-
cate that care quality is high.
The care bundle concept is one such composite meas-
ure that is promoted as a systematic method of monitor-
ing and improving the reliability and quality of health
care [20-22]. A care bundle is simply a number of healthcare interventions grouped together and which normally
have a synergistic relationship that impacts on clinical
outcome [23]. Bundles usually contain three to six com-
ponents which may include clinical interventions such
as care processes, procedures, or diagnostic tests, but
are not deemed suitable to act as comprehensive lists of
all possible care. Selection of appropriate bundle compo-
nents is based on best evidence, local considerations and
may change with time and experiences [24,25].
Specific care bundles have been implemented in a
range of secondary care settings such as paediatric and
adult ICU, medical and surgical wards and Accident and
Emergency departments in North America and the UK
[26,27]. Related clinical outcomes have included signifi-
cant reductions in health care acquired infections,
condition-specific and all-cause mortality, and reduced
re-admission rates of elderly patients, length of ICU stay
and number of ventilation days [20,28-30]. Although
higher compliance rates with bundles are associated with
improved outcomes [31], these are difficult to sustain
because of a combination of system and human factors
which often results in rates below 50% [32-34].
Measuring compliance with bundled interventions on a
composite ‘all-or-nothing’ basis may provide the health-
care team with a more accurate indicator of care quality
and evidence-based care provision [35]. In essence this
means every relevant care component should routinely be
delivered (or considered) for every single patient on time
and every time. Embracing this rationale may act as a
greater prompt to improve patient care than the current
method of monitoring data with individual bundle ele-
ments, which can give a misleading impression of overall
performance.
Evidence of the potential value of composite measures
of care quality in general practice – specifically QOF
data - is limited [36,37]. Given the benefits of the bundle
approach in acute hospital settings, we aimed to develop
care bundles based on those QOF disease areas and indi-
cators in general practice that were judged to be most
suitable. We further aimed to measure individual and
composite compliance with developed care bundles to
highlight the extent of any potential care ‘gaps’ which
may point to opportunities for further improvement.
Methods
Design of care bundles as proxies for composite
measures
The condition-specific care bundles and associated indi-
vidual components were selected from the ‘Quality and
outcomes framework guidance for GMS contract 2009/
10’ by the authors [15]. Studying QOF data was a prag-
matic choice, as it provided a measure of current
evidence-based clinical practices. We agreed selection
criteria to help identify potentially suitable clinical
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lished guidance [24] and local practical considerations.
All QOF sections and indicators were initially consid-
ered. The selection criteria (Table 1) were applied in a
step-wise manner as illustrated in Figure 1 to exclude
unsuitable indicators and conditions.
Measuring care bundle compliance
Setting and sample size
We emailed a convenience sample of 14 West of
Scotland general practitioners (GPs) who are also senior
medical educators based in the west region of NHS Edu-
cation for Scotland (NES) with details of the proposed
study during February 2011. We invited them to discuss
the invitation with their practice teams and indicate to
us a preparedness to participate.
Data collection
On the 31st March 2011 the practice manager in each
participating practice identified and downloaded the
relevant QOF data requested (using guidance provided)
from local information systems to an encrypted USB
mobile data device. This device was then transported by
the GP educator to the regional office for analysis by the
research team. The 31st March is the date on which
recorded performance by the practice is formally mea-
sured against QOF criteria and associated annual earn-
ings calculated. Practice teams work towards this date all
year to record and achieve the maximum patient care as
all indicators are automatically ‘reset’ on the following
day - 1st April.
Practice managers were asked to indicate the total
number of patients registered on their practice list and
on each disease register. We decided to code ‘exception
reported’ indicators as if they had been met - in other
words that the specified care was ‘delivered’ to patients.
We based this premise on the fact that exception report-
ing has historically accounted for ≤ 1.6% of all QOF
costs [38] and we assumed that the suitability of the care
described by an indicator would have been considered (ifTable 1 Care bundle selection criteria
• A care bundle should relate to a specific clinical condition
• A care bundle should have a minimum of three components
• Care bundle components should describe a specific, measurable
action
• Delivery of every component should be possible for the practice
team.
• Bundle components should be relevant to all patients with that
condition.
• Components must be repeatable, rather than ‘one-off’ actions.
• Components should not duplicate or be a necessary part of each
othernot delivered) for each patient during the exemption
process.
Statistical analysis
Data were uploaded to and coded in Microsoft Office Excel
2007. All patient and practice identifiers were removed im-
mediately, with practices being coded to enable feedback
to be provided. Descriptive statistics were performed using
SPSS v.17.0 to calculate each practice’s compliance as a
percentage for the selected QOF indicators (bundle com-
ponent) and the composite compliance for the selected
clinical conditions (bundles). Overall compliance with care
bundles (composite measures) and their components were
calculated after adding the patients on each disease register
of all the participating practices together.
Results
Care bundles (composite measures) and indicators
Five QOF clinical conditions fulfilled the pre-specified
inclusion criteria: Stroke/TIA, secondary prevention of
coronary heart disease (CHD), diabetes mellitus (DM),
chronic kidney disease (CKD) and chronic obstructive
pulmonary disease (COPD). The 24 retained indicators
are shown in Table 2.
Response rate and demographics
A total of 12/14 practices agreed to participate. Nine
practices were able to provide data in the format
requested to allow meaningful analysis (64.3%). The
combined patient population on the 31st March 2010
was 56,948. The prevalence of the selected clinical con-
ditions in all practices was: CKD 3.4% (range 2.5% to
4.9%), stroke/TIA 2.2% (range 1.7% to 2.7%), diabetes
mellitus 4.2% (range 3.6% to 5.5%), CVD 4.6% (range
4.2% to 6.2%) and COPD 2.3% (range 0.8% to 3.8%). Fur-
ther demographic and disease register details of partici-
pating practices are shown in Table 3.
Composite measures and individual indicator compliance
The minimum and maximum payment thresholds for
the selected indicators ranged from 40-50% and 60-90%
respectively. All practices achieved the minimum thresh-
old for all indicators and the vast majority also achieved
the maximum threshold for most indicators.
The composite measures of the selected conditions
(care bundles) varied for all practices and were as fol-
lows: CKD 69.0% (range 64.0-81.4%), stroke/TIA 74.1%
(range 51.6% to 82.8%), Diabetes mellitus 58.4% (range
50.3% to 65.2%), CVD 64.0% (range 47.8% to 71.9%) and
COPD 82.0 (range 47.9% to 95.8%). Care bundles with
more components such as DM and CVD generally had
lower compliance rates.
The diabetes mellitus care delivered by all practices as
specified by individual indicators ranged from 82.9%
Figure 1 Step-by-step process to select suitable clinical conditions (care bundles) and QOF indicators (bundle components).
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pliance was substantially lower at 58.4%. In other
words, 58.4% of all eligible patients received all the care
specified by the bundle and 41.6% of patients did not
receive one or more care components. For CVD care,individual indicator achievements ranged from 82.6%
(CVD10) to 99.0% (CVD11) with 64.0% of patients re-
ceiving all specified care. The COPD care delivery was
the most reliable, with 82.0% of patients receiving all
components. However, overall the results suggest that
Table 2 Retained clinical conditions and QOF indicators (care bundles and components)
Secondary prevention of Coronary Heart Disease (CHD)
The percentage of patients with coronary heart disease:
CHD6 . . .in whom the last blood pressure reading (measured in the previous 15 months) is 150/90 or less
CHD8 . . .whose last measured total cholesterol (measured in the previous 15 months) is 5 mmol/l or less
CHD9 . . .with a record in the previous 15 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken (unless a
contraindication or side-effects are recorded)
CHD10 . . .who are currently treated with a beta blocker (unless a contraindication or side-effects are recorded)
CHD11 . . .a history of myocardial infarction (diagnosed after 1 April 2003) who are currently treated with an ACE inhibitor or Angiotensin II
antagonist
CHD12 . . .who have a record of influenza immunisation in the preceding 1 September to 31 March
Chronic kidney disease (CKD)
The percentage of patients on the CKD register:
CKD3 . . .whom the last blood pressure reading, measured in the previous 15 months, is 140/85 or less
CKD5 . . .with hypertension and proteinuria who are treated with an angiotensin converting enzyme inhibitor (ACE – I) or angiotensin receptor
blocker (ARB) (unless a contraindication or side effects are recorded)
CKD6 . . .whose notes have a record of a urine albumin: creatinine ratio (or protein: creatinine ratio) test in the previous 15 months
Diabetes mellitus (DM)
The percentage of patients with diabetes:
DM2 . . .whose notes record BMI in the previous 15 months
DM24 . . .in whom the last HbA1c is 8 or less (or equivalent test/reference range depending on local laboratory) in the previous 15 months
DM9 . . .with a record of the presence or absence of peripheral pulses in the previous 15 months
DM10 . . .with a record of neuropathy testing in the previous 15 months
DM12 . . .in whom the last blood pressure is 145/85 or less
DM15 . . .with a diagnosis of proteinuria or micro-albuminuria who are treated with ACE inhibitors (or A2 antagonists)
DM17 . . .whose last measured total cholesterol within the previous 15 months is 5 mmol/l or less
DM18 . . .who have had influenza immunisation in the preceding 1 September to 31 March
Chronic obstructive pulmonary disease (COPD)
The percentage of patients with COPD:
COPD10 . . .with a record of FeV1 in the previous 15 months
COPD13 . . .who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the MRC dyspnoea
score in the preceding 15 months
COPD8 . . .who have had influenza immunisation in the preceding 1 September to 31 March
Stroke and transient ischaemic attack (Stroke/TIA)
The percentage of patients with:
STROKE6 . . .a history of TIA or stroke in whom the last blood pressure reading (measured in the previous 15 months) is 150/90 or less
STROKE8 . . .TIA or stroke whose last measured total cholesterol (measured in the previous 15 months) is 5 mmol/l or less
STROKE12 . . . with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record that an anti-platelet agent (aspirin, clopidogrel,
dipyridamole or a combination), m or an anti-coagulant is being taken (unless a contraindication or side-effects are recorded)
STROKE10 . . .TIA or stroke who have had influenza immunisation in the preceding 1 September to 31 March
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level of variation within and between practices in evi-
dence based care delivery and arguably therefore pro-
vides a more informed and discriminatory measure of
care quality than the current, largely homogenous ap-
proach. The variation in the individual indicator and
composite measures for each clinical condition and
practice can be observed in Table 3.Discussion
Main findings
This small study is the first known attempt to measure
composite care delivery for specific clinical conditions in
UK primary care using a care bundle approach. We
identified five suitable clinical conditions for care bun-
dles: COPD, CKD, DM, TIA/Stroke and CHD. Three to
eight components were chosen and adapted from QOF
Table 3 Individual indicator and composite measures of patient care for selected clinical conditions by general practice for the period 01/04/2010-31/03/2011
Clinical conditions Payment Participating general practices – codes A-I Total
& Indicators Points* Threshold A B C D E F G H I
All patients = n Min-Max 7613 2277 2893 4567 12850 10939 3507 4600 7702 56948
CKD n(%) 246 (3.2) 111 (4.9) 86 (3.0) 151 (3.3) 321 (2.5) 535 (4.9) 97 (2.8) 172 (3.7) 194 (2.5) 1913 (3.4)
CKD3 11 40-70% 186 (75.2) 72 (64.9) 64 (74.4) 116 (76.8) 255 (79.4) 421 (78.7) 85 (87.6) 85 (87.6) 143 (73.7) 1472 (76.9)
CKD5 9 40-80% 245 (99.6) 110 (99.1) 86 (100) 151 (100) 316 (98.4) 532 (99.4) 96 (99.0) 96 (99.0) 192 (99.0) 1890 (98.8)
CKD6 6 40-80% 211 (85.8) 111 (100) 85 (98.8) 136 (90.1) 282 (87.9) 469 (87.7) 90 (92.8) 90 (92.8) 171 (88.1) 1707 (89.2)
Overall 158 (64.2) 71 (64.0) 64 (74.4) 105 (69.5) 225 (70.1) 380 (71.0) 79 (81.4) 79 (81.4) 129 (66.5) 1320 (69.0)
STROKE/TIA n(%) 173 (2.3) 62 (2.7) 75 (2.6) 100 (2.2) 309 (2.4) 248 (2.3) 67 (1.9) 112 (2.4) 129 (1.7) 1275 (2.2)
STR6 5 40-70% 165 (95.4) 52 (83.9) 67 (89.3) 90 (90.0) 288 (93.2) 226 (91.1) 56 (83.6) 105 (93.8) 118 (91.5) 1167 (91.5)
STR8 5 40-60% 158 (91.3) 48 (77.4) 60 (80.0) 81 (81.0) 283 (91.6) 213 (85.9) 58 (86.6) 95 (84.8) 110 (85.3) 1106 (86.7)
STR12 4 40-90% 166 (96.0) 60 (96.8) 72 (96.0) 96 (96.0) 305 (98.7) 235 (94.8) 65 (97.0) 108 (96.4) 125 (96.9) 1232 (96.6)
STR10 2 40-85% 151 (87.3) 59 (95.2) 73 (97.3) 96 (96.0) 293 (94.8) 234 (94.4) 61 (91.0) 104 (92.9) 124 (96.1) 1195 (93.7)
Overall 129 (74.6) 32 (51.6) 52 (69.3) 66 (66.6) 256 (82.8) 179 (72.2) 43 (64.2) 84 (75.0) 96 (74.4) 945 (74.1)
Diabetes Mellitus n(%) 275 (3.6) 120 (5.3) 159 (5.5) 156 (3.4) 520 (4.0) 458 (4.2) 163 (4.6) 181 (3.9) 366 (4.8) 2398 (4.2)
DM2 3 40-90% 265 (96.4) 120 (100) 159 (100) 151 (96.8) 506 (97.3) 449 (98.0) 159 (97.5) 175 (96.7) 356 (97.3) 2340 (97.6)
DM24 8 40-70% 250 (90.9) 95 (79.2) 140 (88.1) 133 (85.3) 432 (83.1) 359 (78.4) 136 (83.4) 148 (81.8) 296 (80.9) 1989 (82.9)
DM9 3 40-90% 244 (88.7) 119 (99.2) 147 (92.5) 151 (96.8) 475 (91.3) 421 (91.9) 159 (97.5) 165 (91.2) 353 (96.4) 2234 (93.2)
DM10 3 40-90% 244 (88.7) 119 (99.2) 147 (92.5) 150 (96.2) 475 (91.3) 422 (92.1) 159 (97.5) 166 (91.7) 351 (95.9) 2233 (93.1)
DM12 18 40-60% 244 (88.7) 105 (87.5) 144 (90.6) 118 (75.6) 459 (88.3) 375 (81.9) 133 (81.6) 166 (91.7) 329 (89.9) 2060 (85.9)
DM13 3 40-90% 253 (92.0) 119 (99.2) 154 (96.9) 140 (89.7) 484 (93.1) 426 (93.0) 149 (91.4) 153 (84.5) 345 (94.3) 2244 (93.6)
DM22 3 40-90% 269 (97.8) 120 (100.) 157 (98.7) 151 (96.8) 506 (97.3) 442 (96.5) 160 (98.2) 174 (96.1) 361 (98.6) 2346 (97.8)
DM15 3 40-80% 267 (97.1) 116 (96.7) 156 (98.1) 156 (100) 515 (99.0) 458 (100) 160 (98.2) 180 (99.4) 359 (98.1) 2363 (98.5)
DM17 6 40-70% 253 (92.0) 109 (90.8) 145 (91.2) 147 (94.2) 475 (91.3) 396 (86.5) 139 (85.3) 155 (85.6) 313 (85.5) 2132 (88.9)
DM18 3 40-85% 246 (89.5) 118 (98.3) 153 (96.2) 139 (89.1) 492 (94.6) 419 (91.5) 147 (90.2) 162 (89.5) 351 (95.9) 2227 (92.9)
Overall 166 (60.4) 75 (62.5) 103 ( 64.8) 84 (53.8) 339 (65.2) 239 (52.2) 82 (50.3) 100 (55.2) 213 (58.2) 1401 (58.4)
Sec prev. of CHD n(%) 317 (4.2) 128 (5.6) 178 (6.2) 204 (4.5) 547 (4.3) 546 (5.0) 189 (5.4) 203(4.4) 327 (4.2) 2639 (4.6)
CHD6 17 40-70% 300 (94.6) 118 (92.2) 162 (91.0) 174 (85.3) 524 (95.8) 495 (90.7) 166 (87.8) 187 (92.1) 312 (95.4) 2438 (92.4)
CHD8 17 40-70% 294 (92.7) 103 (80.5) 134 (75.3) 186 (91.2) 510 (93.2) 464 (85.0) 155 (82.0) 162 (79.8) 308 (94.2) 2316 (87.8)
CHD9 7 40-90% 293 (92.4) 120 (93.8) 172 (96.6) 199 (97.5) 541 (98.9) 511 (93.6) 172 (91.0) 195 (96.1) 319 (97.6) 2522 (95.6)
CHD10 7 40-60% 295 (93.1) 91 (71.1) 125 (70.2) 184 (90.2) 504 (92.1) 402 (73.6) 131 (69.3) 149 (73.4) 300 (91.7) 2181 (82.6)
CHD11 7 40-80% 312 (98.4) 128 (100) 178 (100) 202 (99.0) 540 (98.7) 539 (98.7) 187 (98.9) 202 (99.5) 325 (99.4) 2613 (99.0)
CHD12 7 40-90% 293 (92.4) 122 (95.3) 172 (96.6) 193 (94.6) 526 (96.2) 524 (96.0) 178 (94.2) 186 (91.6) 313 (95.7) 2507 (95.0)






















Table 3 Individual indicator and composite measures of patient care for selected clinical conditions by general practice for the period 01/04/2010-31/03/2011
(Continued)
COPD n(%) 163 (2.1) 72 (3.2) 92 (3.2) 36 (0.8) 286 (2.2) 298 (2.7) 55 (1.6) 176 (3.8) 142 (1.8) 1320 (2.3)
COPD10 7 40-70% 152 (93.3) 69 (95.8) 85 (92.4) 32 (88.9) 254 (88.8) 273 (91.6) 52 (94.5) 167 (94.9) 74 (52.1) 1158 (87.7)
COPD13 9 50-90% 155 (95.1) 69 (95.8) 85 (92.4) 34 (94.4) 270 (94.4) 280 (94.0) 54 (98.2) 170 (96.6) 137 (96.5) 1254 (95.0)
COPD8 6 40-85% 150 (92.0) 72 (100) 88 (95.7) 35 (97.2) 270 (94.4) 278 (93.3) 53 (96.4) 166 (94.3) 134 (94.4) 1246 (94.4)
Overall 140 (85.9) 69 (95.8) 83 (90.2) 30 (83.3) 231 (80.8) 254 (85.2) 50 (90.9) 157 (89.2) 68 (47.9) 1082 (82.0)
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bundle components was generally high, but substantially
lower overall for the ‘all or nothing’ bundles. We would
suggest that this ‘gap’ in performance may be a more
valid reflection of the variation in expected care delivery
at the patient level than current individual measures
presently indicate.
The ‘gap’ between component and care bundle
compliance
There are at least five possible reasons for the observed
‘gap’ between individual component and overall bundle
compliance. Firstly, the Framework financially incenti-
vizes an individual indicator approach so this becomes
the practice focus. Secondly, some components are eas-
ier to deliver than others. Thirdly, care bundle compli-
ance (the composite measure) will always have a value
equal to or lower than that of the indicator with the low-
est performance - consequently there will always be a
gap, although it is unknown whether or when the size of
the ‘gap’ becomes of clinical significance. Fourthly, the
‘gap’ will usually increase exponentially with the rise in
the number of bundle components. Finally, natural vari-
ation is inherent in all health care systems and will be
affected by the effectiveness and efficiencies of local pro-
cesses and team efforts.
Variation in care is introduced ‘naturally’ through dif-
ferent and often complex patient presentations and ‘arti-
ficially’ through individual clinician differences and
priorities, extenuating circumstances and local systems.
‘Patient characteristics’ and ‘deprivation’ have previously
been identified as the two factors which are strongly
associated with variation (‘the gap’) in primary health
care settings in Scotland [12], England [11,13,39], the
Netherlands [40], Australia [41] and the USA [42].
The care ‘gap’ between components and care bundles
in our study was observed for all clinical conditions and
participating practices. This ‘gap’ (variation) may be at
least partially accounted for by hidden patient and
deprivation factors. The implication may be that the care
bundle method may measure the gap but could not ne-
cessarily help to eliminate it.
In UK secondary care settings, reported compliance
with a variety of clinical care bundles ranges from 19-
52% [32,33]. Low compliance rates have important pa-
tient safety implications, as a positive and significant
association has been found between compliance rates
and clinical outcomes such as mortality [27,28,32]. A
similar association has not yet been shown for primary
care. Although the participating practices’ compliance
with all the selected bundles was ≥ 58% it is not known
whether compliance can be compared meaningfully
across settings and for different care bundles. It would
also be desirable to determine to what degree differentcompliance levels may impact on clinical outcomes in
primary care settings.
The QOF and care bundles
We adapted care bundles from the QOF, currently the
most ambitious, comprehensive and largest P4P scheme
and quality measure in international healthcare and a
‘natural experiment in progress’ [43]. Framework re-
search and experience may therefore be applicable to
our study findings. For example: the Framework can
cause a ‘street lamp effect’, i.e. neglect of health care ac-
tivity and clinical conditions which do not attract finan-
cial incentives; it can create a de-personalizing ‘box
ticking culture’; it is vulnerable to data distortion and
potential gaming; it is accelerating a transition to nurse-
led primary care; there is tension between the different
QOF roles as a quality improvement method, regulatory
framework or remuneration mechanism; the Framework
promotes simplicity over complexity and measurability
over meaningfulness. These valid concerns could simi-
larly be raised about the care bundle method, with no
clear answers at present [19,43-46].
The impact of QOF on clinical outcomes continues to
be debated. There is no evidence of any ‘discernable ef-
fect’ on hypertension-related outcomes [47], while new
depression indicators failed to improve disease detection
or treatment [46]. In addition, associations between
QOF measures and all-cause mortality and emergency
admissions have been found to be ‘small and inconsist-
ent’ [39]. On the other hand, evidence of improved care
quality for patients with specific chronic diseases and a
‘trend towards improvement’ in process and outcome at
least partly attributable to QOF have recently been
reported [44,48-50]. It is unclear what impact (if any)
surrogate measures such as care bundles would have on
clinical outcomes, how this could be feasibly measured
and what period of time would be required.
‘Time-interval’ indicators have been proposed as an al-
ternative and more reliable measure to ‘point-in-time’
indicators to assess care quality [51]. Performance is eval-
uated over a specified period rather than at a single point
in time. Mabotuwana et al applied this approach to hyper-
tension management and found it feasible but with lower
measures for ‘interval indicators’ compared with point-in-
time indicators. The differences, similarities and potential
benefits of any one method, whether care bundles, time-
interval or QQF indicators are unclear.
Care bundle implementation
The care bundle method may be a useful new care qual-
ity measure and help to reduce healthcare variation. It
may also help to better differentiate the care quality of
practices, given that their current QOF scores are now
broadly comparable. To implement the bundle a number
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resistance from practices who are financially disadvan-
taged by ‘lower’ measures than the current thresholds;
accounting for ‘natural’ variation so that practices are not
unfairly penalized; existing information technology sys-
tems would have to be redesigned; a full evaluation to
identify both impact and unintended consequences (e.g. a
proportion of patients may end up receiving ‘no care’)
would be necessary. If this new measure is considered de-
sirable, it would have to be promoted and incentivized.
Reducing variation in quality can decrease costs if the
care ‘gap’ is large, but costs increase as the gap narrows
until there is a net expense [52]. Evaluation of care bun-
dle implementation in some secondary care settings has
found them to be cost-effective [53]. However, imple-
menting interventions require initial financial and re-
source investment. McNeill et al found that only 20/265
(12%) of acute medicine units in the UK had the mini-
mum facilities to comply with the ‘surviving sepsis care
bundle’ [34]. However, the applicability of care bundles
in acute settings cannot be assumed to translate to
QOF-bundled components because care packages over
9-15 month periods.
The financial implications of quality-reporting pro-
grammes vary greatly. The QOF ‘probably’ represents
value for money [54]. Adapting the Framework’s report-
ing system to allow composite quality measures would
require substantial investment and feasibility and accept-
ability concerns would have to be addressed. Known
incentives that facilitate increased practice participation
include: financial payments, staff training and providing
technical support [54,55].
Implementing care bundles and increasing compliance
with them relies not only on individual health care profes-
sionals but even more on the availability of adequate
resources, support systems and leadership. Aligning care
bundles with larger quality improvement initiatives and
providing related training also appears to be an important
factor influencing success and impact [28]. These issues
need to be considered if the care bundle approach is to be
successfully implemented in primary care settings.
Exception reporting and threshold ceilings
The threshold ‘ceiling’ for maximum financial reward is
set at ≤ 90% achievement. Practices could hypothetically
‘stop’ delivering care once they reach these thresholds
without financial penalty. Our findings indicate that
many indicators with relatively low achievement ceilings
were still performed for the vast majority of patients
which seems to suggest that thresholds are an unlikely
reason for the observed ‘gap’.
Exception reporting has previously been found to be
consistent across practices and regions and accounts for
a tiny minority of cases [38]. Concerns that practicesmay be ‘gaming’ results through excessive or inappropri-
ate exception reporting have not been substantiated.
However, exception reporting combined with less than
100% maximum threshold targets introduce an incentive
ceiling [18].
Strengths and limitations
Our findings are based on a small, convenience sample
of practices. We did not take into account patient list
size, geographical distribution (degree of remoteness),
socio-economic class and level of deprivation or preva-
lence of disease. Our findings may still have wider appli-
cation, as different degrees of remoteness, access and
practice size do not significantly contribute to variation
in care quality as measured by QOF results [56,57]. A
recent review found that inequalities in chronic disease
management have largely persisted after introduction of
QOF (even though quality of care may have increased)
[58]. While deprivation is a major contributing cause to
overall care, it has not been shown to affect QOF scores.
For example, Hamilton et al found that the impact of
QOF on diabetes mellitus care was comparable in afflu-
ent and deprived areas [59].
We decided to code exception reported indicators as if
the described care had been delivered. The consequence
was a ‘smaller’ compliance ‘gap’, but one that may have
more acceptability to frontline staff. Exclusion systems
have an important role to help militate against the po-
tential impact of socio-economic, patient and other fac-
tors out-with the practice team’s control. Simple care
processes are mitigated more than complex ones and
the additional work required in deprived areas is not al-
ways being rewarded [60]. We therefore purposefully
selected ‘simple’ care bundle components in preference
to ‘complex’ ones where possible. We accept that there
are many other potential care bundle topics for general
practice. However we chose a pragmatic approach to
give an initial indication on the feasibility of the concept
as applied to QOF data. Others may have chosen alter-
native approaches and clinical topics for bundles.
Conclusions
Based on our small study, we believe that the care bun-
dle approach to QOF data has the potential to provide a
more insightful measure of the quality of evidence based
care provision than the current approach which focuses
on compliance with individual indicators rather than in-
dividual patients. However, issues around the feasibility
and acceptability of the implementation of this method
as part of routine general practices need to be explored.
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